The Latest Breaking News from Novartis

The FDA approved Novartis AG's (NYSE:NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the body. Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company said it had submitted…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Zolgensma is a revolutionary gene therapy that can stop a deadly childhood condition called SMA in its tracks. It’s also one of the most expensive drugs in the world

Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have 

  Novartis (NYSE:NVS) reported its Q4 earnings results on Wednesday, February 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year, 

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE: NVS) Sandoz,